Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions. by Natali, P. G. et al.
Brilish Jo f dCancer(1995) 71L 1243-1247
© 1995 Stockton Press AJl rghts reserved 0007-0920/95 $12.00 M
Expression of fibronectin, fibronectin isoforms and integrin receptors in
melanocytic lesions
PG Natalil, MR Nicotra', F Di Filippo' and A Bigotti'
'Regina Elena Cancer Institute and lInstitute ofBiomedical Technologies CNR, 00161 Rome, Italy.
Smar) In vitro studies have demonstrated that fibronectin (FN) can deliver a mitogenic signal to quiescent
human melanoma cells and that the mS:P-integrin receptor mediates this stimulus. In view of this finding we
have analysed the in vivo expression of FN. and of ED-A and ED-B FN isoforms. in benign and malignant
lesions of melanocyte origin. In the same specimens the expression of fibronectin integrin receptors was
evaluated. The results demonstrate that, while detection of FN does not correlate with transformation and
tumour progression, the expression of the two isoforms is associated with transformation and that only the
ED-A vanrant is found in metastases. Integrin phenotyping disclosed that MIA expression is associated with
tumour progression, aE 3 is a marker of transformation. X4 is rarely expressed and at, is expressed by about
5000 and 30% of the primary and metastatic lesions respectively. Taken together, the results of this study
demonstrate that transformation and tumour progression of the melanocyte lineage are associated with
modulation of expression of FN isoforms and FN integrin receptors. Furthermore, the expression of
-integnn in a considerable percentage of pnrmary and metastatic lesions indicates that FN may deliver a
proliferative stimulus to melanoma cells in vivo.
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Interactions between epithelia and connective tissues play a
major functional role dunrng embryogenesis. tissue repair and
tumour growth (Bissel et al.. 1982; Bronner-Fraser. 1986;
Korhonen et al.. 1990; Albelda. 1993). More recently these
interactions have been shown to be mediated mainly by the
integrin superfamily of molecules (Albelda et al.. 1990;
Hemler, 1990; Hynes. 1992). These heterodimeric transmem-
brane glycoproteins can modulate gene expression and differ-
entiation by interacting with cytoskeletal components (Hor-
vitz et al., 1986; Menko et al.. 1987; Werb et al., 1989;
Adams et al., 1990; Albelda et al., 1990), thus acting as signal
transducing molecules. Although a number of in vitro studies
have extensively documented that malignant transformation
results in qualitative as well as quantitative changes in integ-
nn expression (Juliano et al.. 1993) a more complete app-
reciation of the biological relevance of integrins in tumour
growth and metastasis requires in vivo analysis of autoch-
thonous tumours. Malignant cutaneous melanoma is a
human malignancy which, because of its development in
well-defined stages (Clark et al., 1986) and its relative ease of
propagation in culture (Herlyn et al., 1985), offers the pos-
sibility of a critical comparison of in vitro and in situ integrin
expression, Recent in vitro studies have demonstrated that
fibronectin (FN) possesses mitogenic activity in melanoma
cells and that this stimulus is mediated by the cx5,'P
heterodimer (Mortanrni et al., 1993). In the present study we
have analysed the expression of FN and two FN isoforms in
benign and malignant lesions of the melanocyte lineage. This
analysis has been compared with the expression of the major
FN receptors of the integrin family.
Material and metbods
Tissue specimens. inmunohistochemistry
Surgical biopsies of naevocytic naevi (nine cases) and
primary and metastatic melanoma (15 and 26 cases respec-
tively), were obtained from the Surgical Pathology Division
of the Regina Elena Cancer Institute. Tissue samples were
immediately snap frozen in liquid nitrogen. From each speci-
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men 4 tLm cryostat sections were obtained and were fixed in
absolute acetone for 10 min. Sections were either immediately
used in immunohistochemical assays or kept frozen at
-2O°C with no loss of immune reactivity. Fixed sections
stained with 1% toluidine blue were used to evaluate the
histological features of the lesions. Histological diagnosis was
done according to Clark (1972). Tumour thickness was evalu-
ated according to Breslow (1975).
Indirect immunoperoxidase stain employed primary MAbs
at concentrations ranging from 10 to 30 gml-' and a com-
mercially available avidin-biotin staining kit (Vector
Laboratories, Burlingame, CA, USA). Negative controls con-
sisted of tissue sections from which incubation with primary
antibody was omitted. Selected tissue substrates were used as
positive controls. Reaction product was detected using 3-
amino-9-ethylcarbazole as a chromogenic substrate and
Mayer's haematoxylin as nuclear counterstain.
Monoclonal antibodies
The murine MAbs IST4, IST9 (Borsi et al.. 1987). BC-1
(Carnemolla et al., 1989) recognising total tissue fibronectin
(FN-T), ED-A (FN-A) and ED-B (FN-B) FN isoforms
respectively were kindly provided by Dr L Zardi (Laboratory
of Cell Biology, Istituto Nazionale Tumori. Genoa, Italy).
MAb M-kid2 specific for the aC3 01 heterodimer was produced
as described previously (Bartolazzi et al., 1991). MAbs to at
(M142) and a,./ 3 (M609) integrins were purchased from
Chemicon Laboratories. (Temecula, CA, USA). MAb to M4
(lOP49d) and to as (lOP49e) chains were obtained from
Immunotech (Marseille, France).
Resuts
Immunohistochemical evaluation of the three forms of FN in
normal skin samples from different body sites demonstrated
that, while no B isoform is expressed at detectable level, total
and A FN display an overlapping distribution. The two
molecules are distributed with an interrupted pattern along
the dermal-epidermal junction and the basement membrane
of sebaceous and sweat glands. Scattered reaction product is
observable in the papillary and reticular dermis. The results
of the immunohistochemical evaluation of the expression of
FN, FN isoforms and integrin receptors in benign and malig-
nant lesions of melanocyte origin are summarized in Table I.xFonedinrcecprse i miiauip nuioma
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Table I Patterns of expression of total FN (FN-T), FN isoforms (FN-A. FN-B) and
integrin receptors in benign and malignant lesions of the melanocyte lineage
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Patterns of expression of TN and TN isoforms: a, homogeneous and/or heterogeneous
cellular stain; b, stain of minor interstitial septa with occasional stain of single cells
and or small cell nests; -, no stain or stain limited to the major interstitial septa; NT, not
tested; RGP, radial growth phase; VGP, vertical growth phase. Patterns of expression of
integrin receptors: -, no stain; +/-, weak homogeneous stain; +, homogeneous stain;
+ +. strong homogeneous stain; v, stain of variable intensity; is, stain of isolated areas
accounting for 20% of the lesion. In naevic lesions the stain was mainly restricted to A
type cells.
Total FN was detectable in all types of lesions with two
major distribution patterns. The glycoprotein was distributed
either homogeneously or with a stippled pattern around
small single-cell nests or was mainly present in minor inter-
stitial septa which surround cell nests of variable size. While
the latter pattern was predominantly observed in benign
naevocytic naevi and in primary tumours (Figure la), the
former was frequently seen in metastatic melanoma (Figure
lb and c). Staining of the same lesions with MAb to FN-A
and FN-B isoforms demonstrated that the two molecules are
detectable only in malignant lesions. While both isoforms
could be detected in a small portion of primary tumours the
metastases almost invariably displayed expression of the FN-
A variant only. The FN promiscuous receptors exhibit the
following distribution patterns. Expression of the aC41
heterodimer appeared to increase with the degree of inva-
siveness of primary tumours (Figure Id-f).
Seventy-three per cent of the metastatic lesions were a3/p,
positive. Expression of the O,/P3 receptor, while associated
with transformation (i.e. differential expression between
benign and malignant lesions), did not display a significant
relationship with degree of the tumour invasiveness in the
series of primary tumours studied (Figure Ig-i). Eighty-five
per cent of the metastases were a1/P positive. The analysis of
the distribution of the FN receptors which utilise the E,.
chain, i.e. PI and P6, demonstrated that these heterodimers
characterise the phenotype of the melanocyte lineage with no
apparent modulation in the various lesions studied. The
evaluation of the FN highly specific integrin receptors disc-
losed that the one which utilises the a, heavy chain is rarely
expressed at detectable levels in the melanocytic lineage. On
the contrary, the a5-containing receptor which is expressed
with no apparent relationship with transformation and
tumour progression can be detected in about 50% and 30%
of the primary and metastatic tumours respectively. The
results reported in Table II clearly demonstrate that the
above described phenotype is maintained in multiple metas-
tases analysed in three patients.
3
4
5
6
7
8
9A combination of in vitro and in situ studies has disclosed
that melanoma cells express a panoply of integrin receptors
(Kramer et al.. 1991) but that distinct integrin repertoires
characterise transformation and progression of this neoplasm
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(Hart et al.. 1991). This multistep process seems likely to be
mediated by multiple adhesive interactions with the extracel-
lular matrix as well as by growth-modulating stimuli. The
latter can be delivered from different ligands either directly
(Panayotou et al.. 1989) or indirectly, owing to the complex-
ing of extracellular matrix (ECM) macromolecules with
Ab
'm,
Figure 1 Immunohistochemical analysis of the expression of FN. FN isoforms and FN receptors in melanocyte lesions as detected
by indirect immunoperoxidase stain on 4 glm cryostat sections. In a primary tumour FN is distributed in the minor interstitial septa
which surround tumour cell nests of variable size (arrows) (a). FN-A (b) and FN-B (c) are highly expressed in a case of metastatic
melanoma. While m,/Pl is barely detectable in an intradermal naevus (d. arrow; the dark stain is produced by melanin granules) the
heterodimer is strongly expressed in an invasive pnrmary (2.4 mm thick) (e) and a metastatic (f) tumour. a., is not detectable in an
intradermal naevus (g. asterisk) but is expressed at high level in a primary (1) and a metastatic (i) melanoma. ep = epidermis
(original magnification x 160).Fi,bnetin ecepbrs in mganS maoma
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Tabk II Patterns of expression of total FN (FN-T). FN isoforms (FN-A. FN-B) and integrin
receptors in multiple autologous melanoma metastases
FNv
Patient Metastasis T A B 3 1 P3 (pi A6) M4
Pi I a a a v v v - is
2 b a - v v vr + - is
Pa 1 a a - + + v v
2 b a - v ++ v
3 a b - v + + v v is
Fa 1 a a - v + + +
2 a b - v v ± NT
3 a b b - v +
Patterns ofexpression of TN and TN isoforms: a, homogeneous and or heterogeneous cellular stain;
b, stain of minor interstitial septa with occasional stain of single cells and,or small cell nests; -, no
stain or stain limited to the major interstitial septa; NT, not tested. Patterns of expression of
integrin receptors: -, no stain; +,i-, weak homogeneous stain; +, homogeneous stain; + +. strong
homogeneous stain; v, stain of variable intensity; is, stain of isolated areas accounting for 20% of
the lesion.
growth factors (Nathan et al.. 1991: Yaoi et al., 1991).
Fibronectin has recently been shown to convey a mitogenic
signal in vitro to human melanoma cells through binding to
the asx P highly specific receptor (Mortarini et al., 1993). In
view of this finding it was of interest to evaluate in mela-
noma cells in situ the integrin phenotype that might mediate
interactions in vivo with this abundant ECM component. To
this end we performed an extensive immunohistochemical
analysis of benign and malignant melanocyte lesions aimed at
establishing the in situ expression of FN and two of its
isoforms and the integnrn receptors.
We show here that total FN is widely expressed in melano-
cytic lesions with no apparent relationship with transforma-
tion, tumour progression and metastatic phenotype. The
evaluation of the FN-A and FN-B isoforms on the other
hand has confirmed that their expression is enhanced by
malignant transformation (Carnemolla et al.. 1989) and has
demonstrated that only the FN-A variant is expressed in
metastatic lesions. Although the biological basis of this differ-
ential expression of the two isoforms is presently unclear, the
demonstration that melanoma cells can produce transforming
growth factor beta (TGF-P) (Rodeck et al., 1994), which has
the ability to increase preferentially the expression of the
FN-A isoform (BaLza et al., 1988), may account for this
finding. It is interesting in this context that increase in exp-
ression of the ED-A mRNA has been found to be closely
associated with invasiveness of hepatocarcinomas (Oyama et
al.. 1989). The study of the third known FN isoform, the
IIICS variant (Borsi et al., 1991), could not be performed
because of the present lack of specific antibodies.
The analysis of the expression of the integrin receptors for
FN has revealed a complex repertoire. The 4/1I heterodimer,
which has been shown to modulate adhesion of melanoma
cells to FN in vitro (Mould et al., 1991) and to control
melanoma metastasis in an 'in vivo' model (Qian et al., 1994),
is rarely expressed by human melanoma cells in vivo. Expres-
sion of x, does not appear to be significantly associated with
transformation and tumour progression. On the other hand,
as characterises the phenotype of about 50% and 30% of the
primary and metastatic lesions respectively, thus confirming
the in vitro finding (Mortarini et al., 1993) that a subset of
tumours may be susceptible to the mitogenic activity of FN.
This finding may have some practical implications since the
mitogenic activity (Mortarini et al.. 1993) of FN as well as its
ability to modulate the metastatic behaviour of melanoma
cells (Humphries et al., 1991) has been shown to be antag-
onised by the hydrophilic amino acid peptides Arg-GLv-Asp
located in the cell-binding domain of FN. The detection of a;
also in naevic cells which display no proliferative activity
raises the question of whether the ability of this heterodimer
to transduce a mitogenic signal differs according to the stage
of differentiation, perhaps through changes in receptor
molecule density, requirement for a co-stimulatorv signal or
presence of variant forms of the heterodimer (Hynes, 1992).
In this regard the lack of expression of distinct FN isoforms
suggests that variants of the ligand are unlikely to influence
the receptor's functional activity in naevic cells.
Although our tissue phenotyping could not distinguish
t/Pl from M,/P6 heterodimer, these two highly specific FN
receptors do not appear to undergo modulation in the mela-
nocyte lineage. The results of the evaluation of highly pro-
miscuous receptors for FN confirm the increasing expression
ofM311 with tumour progression (Natali et al., 1993) and the
transformation-associated modulation of the Oa 3 integrin
(Albelda et al., 1990).
In conclusion, the results of the present study have demon-
strated that FN expression remains relatively stable but alter-
native RNA splicing is differently regulated during melanoma
progression. This contrasts with other ECM glycoproteins
which are modulated during melanoma progression (Natali et
al., 1985, 1990). Although this in vivo analysis cannot estab-
lish to what extent FN is derived by melanocyte cells, this
lineage is known to have the ability to synthesise and release
this macromolecule (McClenic et al., 1989). Furthermore, the
expression of a combination of highly promiscuous and
specific integrin receptors suggests that the interactions with
this ubiquitous ECM glycoprotein may, at least in part,
account for the well-known property of this malignancy to
metastasise to many anatomical sites (Rosai. 1981).
Finally, in view of the ability of TGF-P to bind to FN
(Fava and McClure, 1987) this ECM glycoprotein appears
capable of modulating tumour growth by multiple mechan-
isms e.g. cell adhesion by interacting with various integrin
receptors, direct mitogenic activity through selected integrin
molecules, or growth control stimuli (Rodeck et al., 1994)
through bound growth factors. Additional work using well-
defined experimental models may eventually confirm this
hypothesis.
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